683241-86-3

Usage

Uses

Used in Pharmaceutical Industry:
4-BROMO-5-(TRIFLUOROMETHYL)-2-NITROBENZENAMINE is used as a chemical intermediate for the synthesis of various pharmaceuticals, due to its ability to be incorporated into the molecular structures of potential drugs, enhancing their therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 4-BROMO-5-(TRIFLUOROMETHYL)-2-NITROBENZENAMINE is utilized as a precursor in the development of agrochemicals, contributing to the creation of compounds that can improve crop protection and yield.
Used in Material Science:
4-BROMO-5-(TRIFLUOROMETHYL)-2-NITROBENZENAMINE is employed as a component in material science for its potential to be part of the composition of new materials with specific properties, such as those with enhanced stability or reactivity.
Used in Organic Synthesis:
As a key intermediate in organic synthesis, 4-BROMO-5-(TRIFLUOROMETHYL)-2-NITROBENZENAMINE is used for the preparation of organic compounds, taking advantage of its reactive functional groups to form a wide array of products.

Upstream product

• 402-14-2 2-nitro-5-(trifluoromethyl)aniline 
• 393-36-2 4-bromo-3-(trifluoromethyl)aniline 
• 41513-05-7 N-(4-bromo-3-trifluoromethylphenyl)acetamide 
• 156425-51-3 N-(4-bromo-2-nitro-5-trifluoromethyl-phenyl)-2,2,2-trifluoro-acetamide 
• 157554-76-2 N-[4-bromo-2-nitro-5-(trifluoromethyl)phenyl]acetamide 

Downstream Products

• 1345117-61-4 2,6-difluoro-N-(5-(6-(trifluoromethyl)benzo[c][1,2,5]thiadiazol-5-yl)pyridin-2-yl)benzamide 
• 683243-08-5 N-(4-(trifluoromethyl)benzyl)-6-(trifluoromethyl)-2-(4-(3-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-5-ylamine 
• 157590-60-8 4-bromo-5-(trifluoromethyl)benzene-1,2-diamine 

Relevant academic research and scientific papers

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS

This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

Benzimidazole Modulators of VR1

The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.

Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H- benzimidazoles

The vanilloid receptor-1 (VR1 or TRPV1) is a membrane-bound, nonselective cation channel that is predominantly expressed by peripheral neurons sensing painful stimuli. TRPV1 antagonists produce antihyperalgesic effects in animal models of inflammatory and neuropathic pain. Herein, we describe the synthesis and the structure-activity relationships of a series of 2-(4-pyridin-2- ylpiperazin-1-yl)-1H-benzo-[d]imidazoles as novel TRPV1 antagonists. Compound 46ad was among the most potent analogues in this series. This compound was orally bioavailable in rats and was efficacious in blocking capsaicin-induced flinch in rats in a dose-dependent manner. Compound 46ad also reversed thermal hyperalgesia in a model of inflammatory pain, which was induced by complete Freund's adjuvant (CFA).

BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS

Compounds of formula (I) are useful in the treatment of vanilloid-receptor-meditated diseases, such as inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis.